Sincalide
drug drugOn this page
Also known as Cck c-terminal octapeptideCck-8Cck-8sCholecystokinin c-terminal octapeptideKinevacSincalidaSQ 19844SQ-19844AspTyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2cholecystokininAsp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-PheDY(SO3H)MGWMDF(CCK8)Cholecystokinin-8cholecystokinin 8Cholecystokinin OctapeptideSID144207030SID144206508
Summary
Sincalide (CHEMBL1121) is an approved protein (ATC V04CC03) targeting CCKAR and CCKBR.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: V04CC03
- Targets: 2 (CCKAR, CCKBR)
- Clinical trials: 5
- Chemistry: 1143.3 Da · C49H62N10O16S3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1121 |
| Name | Sincalide |
| Type | Protein |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 9833444 |
| ATC | V04CC03 |
| Molecular formula | C49H62N10O16S3 |
| Molecular weight | 1143.3 |
| InChIKey | IZTQOLKUZKXIRV-YRVFCXMDSA-N |
SMILES: CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
IUPAC name: (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
Also known as: Cck c-terminal octapeptide, Cck-8, Cck-8s, Cholecystokinin c-terminal octapeptide, Kinevac, Sincalida, Sincalide, SQ 19844, SQ-19844, CCK-8S, AspTyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2, CCK-8
Patent coverage: 19,499 distinct patent families (27,601 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26,041 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CCKAR | CCK1 receptor | Agonist | 0% | P32238 | |
| CCKBR | CCK2 receptor | Full agonist | 10 | 0.3% | P32239 |
Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Cholecystokinin receptor type A, Cholecystokinin receptor, Cholecystokinin receptor, Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor.
Bioactivity
ChEMBL activities: 93 potent at pChembl ≥ 5 of 93 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CCKAR | 10.36 | EC50 | 0.04 | nM | CHEMBL_ACT_19108777 |
| CCKBR | 10.3 | EC50 | 0.05 | nM | CHEMBL_ACT_1003427 |
| P30551 | 10.05 | Ki | 0.09 | nM | CHEMBL_ACT_723347 |
| P30551 | 10.05 | Ki | 0.09 | nM | CHEMBL_ACT_786164 |
| CCKBR | 10.03 | EC50 | 0.09 | nM | CHEMBL_ACT_2555656 |
| CCKAR | 10 | EC50 | 0.1 | nM | CHEMBL_ACT_1003425 |
| P30551 | 10 | IC50 | 0.1 | nM | CHEMBL_ACT_271156 |
| P30551 | 10 | IC50 | 0.1 | nM | CHEMBL_ACT_288689 |
| P30551 | 10 | IC50 | 0.1 | nM | CHEMBL_ACT_598429 |
| P30551 | 10 | IC50 | 0.1 | nM | CHEMBL_ACT_638926 |
| CCKAR | 9.95 | IC50 | 0.11 | nM | CHEMBL_ACT_19108665 |
| CCKBR | 9.92 | IC50 | 0.12 | nM | CHEMBL_ACT_16501829 |
| CCKBR | 9.92 | IC50 | 0.12 | nM | CHEMBL_ACT_16838414 |
| CCKAR | 9.89 | IC50 | 0.13 | nM | CHEMBL_ACT_16501830 |
| CCKAR | 9.89 | IC50 | 0.13 | nM | CHEMBL_ACT_16838413 |
| CCKBR | 9.64 | IC50 | 0.23 | nM | CHEMBL_ACT_562031 |
| CCKBR | 9.55 | Ki | 0.28 | nM | CHEMBL_ACT_1028557 |
| CCKBR | 9.55 | Ki | 0.28 | nM | CHEMBL_ACT_1167746 |
| Q63931 | 9.55 | Ki | 0.28 | nM | CHEMBL_ACT_1255899 |
| CCKAR | 9.55 | Ki | 0.28 | nM | CHEMBL_ACT_2381367 |
| Q63931 | 9.55 | IC50 | 0.28 | nM | CHEMBL_ACT_719264 |
| Q63931 | 9.55 | Ki | 0.28 | nM | CHEMBL_ACT_71989 |
| CCKBR | 9.54 | IC50 | 0.29 | nM | CHEMBL_ACT_19108721 |
| CCKBR | 9.52 | Ki | 0.3 | nM | CHEMBL_ACT_1022648 |
| P56481 | 9.52 | IC50 | 0.3 | nM | CHEMBL_ACT_271155 |
| P56481 | 9.52 | IC50 | 0.3 | nM | CHEMBL_ACT_288690 |
| P56481 | 9.52 | IC50 | 0.3 | nM | CHEMBL_ACT_290965 |
| P56481 | 9.52 | IC50 | 0.3 | nM | CHEMBL_ACT_598428 |
| P56481 | 9.52 | IC50 | 0.3 | nM | CHEMBL_ACT_638927 |
| O08786 | 9.52 | Ki | 0.3 | nM | CHEMBL_ACT_674447 |
| CCKBR | 9.52 | Ki | 0.3 | nM | CHEMBL_ACT_888977 |
| CCKBR | 9.52 | Ki | 0.3 | nM | CHEMBL_ACT_915434 |
| CCKBR | 9.5 | IC50 | 0.32 | nM | CHEMBL_ACT_1003424 |
| CCKBR | 9.5 | IC50 | 0.32 | nM | CHEMBL_ACT_275520 |
| CCKBR | 9.5 | IC50 | 0.32 | nM | CHEMBL_ACT_468760 |
| CCKBR | 9.5 | IC50 | 0.32 | nM | CHEMBL_ACT_976158 |
| CCKBR | 9.5 | IC50 | 0.32 | nM | CHEMBL_ACT_991302 |
| CCKBR | 9.46 | IC50 | 0.35 | nM | CHEMBL_ACT_181154 |
| CCKBR | 9.46 | IC50 | 0.35 | nM | CHEMBL_ACT_752823 |
| CCKAR | 9.43 | IC50 | 0.37 | nM | CHEMBL_ACT_2381345 |
| CCKBR | 9.43 | Ki | 0.37 | nM | CHEMBL_ACT_2381368 |
| CCKAR | 9.41 | IC50 | 0.39 | nM | CHEMBL_ACT_1003423 |
| Q63931 | 9.4 | IC50 | 0.4 | nM | CHEMBL_ACT_642093 |
| CCKAR | 9.4 | IC50 | 0.4 | nM | CHEMBL_ACT_991301 |
| P30553 | 9.39 | Ki | 0.41 | nM | CHEMBL_ACT_723348 |
| P30553 | 9.39 | Ki | 0.41 | nM | CHEMBL_ACT_786165 |
| O08786 | 9.31 | Ki | 0.49 | nM | CHEMBL_ACT_486919 |
| CCKBR | 9.3 | EC50 | 0.5 | nM | CHEMBL_ACT_19108833 |
| P30551 | 9.3 | IC50 | 0.5 | nM | CHEMBL_ACT_768334 |
| P30551 | 9.28 | Ki | 0.52 | nM | CHEMBL_ACT_1024475 |
| P30553 | 9.22 | Ki | 0.6 | nM | CHEMBL_ACT_1022650 |
| P30553 | 9.22 | Ki | 0.6 | nM | CHEMBL_ACT_71990 |
| Q63931 | 9.22 | Ki | 0.6 | nM | CHEMBL_ACT_735295 |
| P30553 | 9.2 | EC50 | 0.63 | nM | CHEMBL_ACT_1022651 |
| CCKAR | 9.2 | IC50 | 0.63 | nM | CHEMBL_ACT_275519 |
| CCKAR | 9.2 | IC50 | 0.63 | nM | CHEMBL_ACT_468759 |
| P30553 | 9.2 | EC50 | 0.63 | nM | CHEMBL_ACT_71991 |
| Q63931 | 9.19 | Ki | 0.64 | nM | CHEMBL_ACT_1028558 |
| Q63931 | 9.19 | Ki | 0.64 | nM | CHEMBL_ACT_1167747 |
| Q63931 | 9.19 | Ki | 0.64 | nM | CHEMBL_ACT_1255900 |
| CCKBR | 9.19 | Ki | 0.65 | nM | CHEMBL_ACT_549882 |
| CCKBR | 9.19 | Ki | 0.64 | nM | CHEMBL_ACT_71988 |
| Q63931 | 9.15 | Ki | 0.7 | nM | CHEMBL_ACT_1022649 |
| P30553 | 9.15 | Ki | 0.7 | nM | CHEMBL_ACT_735296 |
| Q63931 | 9.15 | Ki | 0.7 | nM | CHEMBL_ACT_915435 |
| P30551 | 9.1 | IC50 | 0.8 | nM | CHEMBL_ACT_639987 |
| CCKBR | 9.04 | IC50 | 0.92 | nM | CHEMBL_ACT_2381346 |
| P30551 | 9 | IC50 | 1 | nM | CHEMBL_ACT_290964 |
| P30553 | 9 | IC50 | 1 | nM | CHEMBL_ACT_768335 |
| P30551 | 8.98 | IC50 | 1.04 | nM | CHEMBL_ACT_1468126 |
| P30551 | 8.98 | IC50 | 1.04 | nM | CHEMBL_ACT_67483 |
| P30551 | 8.98 | IC50 | 1.04 | nM | CHEMBL_ACT_707122 |
| P30551 | 8.97 | IC50 | 1.08 | nM | CHEMBL_ACT_144020 |
| CCKAR | 8.9 | IC50 | 1.26 | nM | CHEMBL_ACT_976157 |
| P56481 | 8.89 | IC50 | 1.3 | nM | CHEMBL_ACT_971362 |
| CCKAR | 8.88 | IC50 | 1.32 | nM | CHEMBL_ACT_181153 |
| CCKAR | 8.88 | IC50 | 1.32 | nM | CHEMBL_ACT_562030 |
| CCKAR | 8.88 | IC50 | 1.32 | nM | CHEMBL_ACT_752822 |
| CCKBR | 8.8 | IC50 | 1.6 | nM | CHEMBL_ACT_719263 |
| CCKAR | 8.7 | EC50 | 2 | nM | CHEMBL_ACT_976154 |
| P30553 | 8.55 | Ki | 2.8 | nM | CHEMBL_ACT_1024476 |
| O08786 | 8.52 | Ki | 3 | nM | CHEMBL_ACT_821651 |
| P30553 | 8.25 | IC50 | 5.6 | nM | CHEMBL_ACT_1468127 |
| P30553 | 8.25 | IC50 | 5.6 | nM | CHEMBL_ACT_67484 |
| P30553 | 8.25 | IC50 | 5.6 | nM | CHEMBL_ACT_707123 |
| P30553 | 8.22 | IC50 | 6 | nM | CHEMBL_ACT_144021 |
| CCKBR | 8.09 | IC50 | 8.2 | nM | CHEMBL_ACT_642094 |
| P30551 | 8.06 | Ki | 8.71 | nM | CHEMBL_ACT_486920 |
| CCKBR | 7.57 | EC50 | 26.92 | nM | CHEMBL_ACT_1712308 |
| CCKBR | 7.57 | EC50 | 27 | nM | CHEMBL_ACT_1712309 |
| CCKAR | 7.55 | EC50 | 28 | nM | CHEMBL_ACT_1712228 |
| CCKAR | 7.55 | EC50 | 28.18 | nM | CHEMBL_ACT_1712289 |
| O08786 | 6.75 | Ki | 180 | nM | CHEMBL_ACT_811002 |
Target pathways
Aggregated over 2 target gene(s): CCKAR, CCKBR.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Peptide ligand-binding receptors | 2 | CCKAR, CCKBR |
| G alpha (q) signalling events | 2 | CCKAR, CCKBR |
| Signal Transduction | 1 | CCKAR |
| Signaling by GPCR | 1 | CCKAR |
| Class A/1 (Rhodopsin-like receptors) | 1 | CCKAR |
| GPCR downstream signalling | 1 | CCKAR |
| GPCR ligand binding | 1 | CCKAR |
| Gastrin-CREB signalling pathway via PKC and MAPK | 1 | CCKBR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G protein-coupled receptor signaling pathway | 2 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 2 |
| cholecystokinin signaling pathway | 2 |
| signal transduction | 2 |
| neuron migration | 1 |
| axonogenesis | 1 |
| forebrain development | 1 |
| cellular response to hormone stimulus | 1 |
| regulation of hormone secretion | 1 |
| gastric acid secretion | 1 |
| cell surface receptor signaling pathway | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| neuropeptide signaling pathway | 1 |
| positive regulation of cell population proliferation | 1 |
| pH reduction | 1 |
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00706381 | PHASE3 | COMPLETED | Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs) |
| NCT00004414 | Not specified | COMPLETED | Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis |
| NCT01656057 | Not specified | COMPLETED | The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion |
| NCT02445508 | Not specified | COMPLETED | Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion |
| NCT02497313 | Not specified | COMPLETED | Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
122 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| AFATINIB | ChEMBL + PubChem | Phase 4 (approved) | CCKAR, CCKBR |
| Docetaxel | ChEMBL + PubChem | Phase 4 (approved) | CCKAR, CCKBR |
| RIFAMPIN | ChEMBL + PubChem | Phase 4 (approved) | CCKAR, CCKBR |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| CHLORDIAZEPOXIDE | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| INDOCYANINE GREEN ACID FORM | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| NITAZOXANIDE | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| RIFAXIMIN | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| RIMONABANT | ChEMBL | Phase 4 (approved) | CCKAR, CCKBR |
| CE-326597 | ChEMBL | Phase 2 | CCKAR, CCKBR |
| DEVAZEPIDE | ChEMBL | Phase 2 | CCKAR, CCKBR |
| NETAZEPIDE | ChEMBL | Phase 2 | CCKAR, CCKBR |
| Abiraterone | PubChem | Approved | CCKAR, CCKBR |
| acetylcysteine | PubChem | Approved | CCKAR, CCKBR |
| Aclidinium Bromide | PubChem | Approved | CCKAR, CCKBR |
| Acyclovir | PubChem | Approved | CCKAR, CCKBR |
| Allopurinol | PubChem | Approved | CCKAR, CCKBR |
| Almotriptan | PubChem | Approved | CCKAR, CCKBR |
| Alogliptin | PubChem | Approved | CCKAR, CCKBR |
| aminolevulinic acid | PubChem | Approved | CCKAR, CCKBR |
| Anagrelide | PubChem | Approved | CCKAR, CCKBR |
| Apixaban | PubChem | Approved | CCKAR, CCKBR |
| Bosentan | PubChem | Approved | CCKAR, CCKBR |
| Clofarabine | PubChem | Approved | CCKAR, CCKBR |
| Clozapine | PubChem | Approved | CCKAR, CCKBR |
| Crizotinib | PubChem | Approved | CCKAR, CCKBR |
| Desloratadine | PubChem | Approved | CCKAR, CCKBR |
| Dihydroergotamine | PubChem | Approved | CCKAR, CCKBR |
| Erythromycin | PubChem | Approved | CCKAR, CCKBR |
| Ethambutol | PubChem | Approved | CCKAR, CCKBR |
| Fulvestrant | PubChem | Approved | CCKAR, CCKBR |
| Ganciclovir | PubChem | Approved | CCKAR, CCKBR |
| Gefitinib | PubChem | Approved | CCKAR, CCKBR |
| Glycopyrrolate | PubChem | Approved | CCKAR, CCKBR |
| Leucovorin | PubChem | Approved | CCKAR, CCKBR |
| Linagliptin | PubChem | Approved | CCKAR, CCKBR |
| Methotrexate | PubChem | Approved | CCKAR, CCKBR |
| Olanzapine | PubChem | Approved | CCKAR, CCKBR |
| Olmesartan Medoxomil | PubChem | Approved | CCKAR, CCKBR |
| Pramipexole | PubChem | Approved | CCKAR, CCKBR |
| Propoxyphene | PubChem | Approved | CCKAR, CCKBR |
| Pyrazinamide | PubChem | Approved | CCKAR, CCKBR |
| Rufinamide | PubChem | Approved | CCKAR, CCKBR |
| saxagliptin | PubChem | Approved | CCKAR, CCKBR |
| Sildenafil | PubChem | Approved | CCKAR, CCKBR |
| Tadalafil | PubChem | Approved | CCKAR, CCKBR |
| Tafamidis | PubChem | Approved | CCKAR, CCKBR |
| Tamsulosin | PubChem | Approved | CCKAR, CCKBR |
| Tegaserod | PubChem | Approved | CCKAR, CCKBR |
| Tiotropium Bromide Monohydrate | PubChem | Approved | CCKAR, CCKBR |
| Valacyclovir | PubChem | Approved | CCKAR, CCKBR |
| Valganciclovir | PubChem | Approved | CCKAR, CCKBR |
| ATAZANAVIR | ChEMBL + PubChem | Phase 4 (approved) | CCKAR |
| FIDAXOMICIN | ChEMBL + PubChem | Phase 4 (approved) | CCKBR |
| AMSACRINE | ChEMBL | Phase 4 (approved) | CCKAR |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | CCKBR |
| AZLOCILLIN | ChEMBL | Phase 4 (approved) | CCKBR |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | CCKAR |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | CCKAR |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | CCKAR |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | CCKBR |
| DASATINIB | ChEMBL | Phase 4 (approved) | CCKAR |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | CCKAR |
| DESERPIDINE | ChEMBL | Phase 4 (approved) | CCKAR |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | CCKBR |
| EFAVIRENZ | ChEMBL | Phase 4 (approved) | CCKBR |
| ENCORAFENIB | ChEMBL | Phase 4 (approved) | CCKBR |
| ERLOTINIB | ChEMBL | Phase 4 (approved) | CCKAR |
| FLUNITRAZEPAM | ChEMBL | Phase 4 (approved) | CCKBR |
| FLUOXETINE | ChEMBL | Phase 4 (approved) | CCKBR |
| FLUTRIMAZOLE | ChEMBL | Phase 4 (approved) | CCKBR |
| FLUVASTATIN | ChEMBL | Phase 4 (approved) | CCKAR |
| HYDROXOCOBALAMIN | ChEMBL | Phase 4 (approved) | CCKAR |
| ILOPERIDONE | ChEMBL | Phase 4 (approved) | CCKBR |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | CCKBR |
| LANSOPRAZOLE | ChEMBL | Phase 4 (approved) | CCKBR |
| LEFLUNOMIDE | ChEMBL | Phase 4 (approved) | CCKBR |
| LETERMOVIR | ChEMBL | Phase 4 (approved) | CCKAR |
| LURASIDONE | ChEMBL | Phase 4 (approved) | CCKAR |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | CCKAR |
| NIMESULIDE | ChEMBL | Phase 4 (approved) | CCKAR |
| OSIMERTINIB | ChEMBL | Phase 4 (approved) | CCKAR |
| PACLITAXEL | ChEMBL | Phase 4 (approved) | CCKAR |
| PENTAGASTRIN | ChEMBL | Phase 4 (approved) | CCKBR |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | CCKAR |
| RAMATROBAN | ChEMBL | Phase 4 (approved) | CCKAR |
| RITONAVIR | ChEMBL | Phase 4 (approved) | CCKAR |
| SUNITINIB | ChEMBL | Phase 4 (approved) | CCKAR |
| TAMOXIFEN | ChEMBL | Phase 4 (approved) | CCKBR |
| TELMISARTAN | ChEMBL | Phase 4 (approved) | CCKAR |
| TELOTRISTAT | ChEMBL | Phase 4 (approved) | CCKAR |
| TELOTRISTAT ETHYL | ChEMBL | Phase 4 (approved) | CCKAR |
| TIPRANAVIR | ChEMBL | Phase 4 (approved) | CCKAR |
| NILVADIPINE | ChEMBL | Phase 3 | CCKBR |
| DIPERODON | ChEMBL | Phase 2 | CCKAR |
| GASTRIN | ChEMBL | Phase 2 | CCKBR |
| LINTITRIPT | ChEMBL | Phase 2 | CCKAR |
| LORGLUMIDE | ChEMBL | Phase 2 | CCKBR |
| LOXIGLUMIDE | ChEMBL | Phase 2 | CCKAR |
| PIRENOXINE | ChEMBL | Phase 2 | CCKAR |
Related Atlas pages
- Genes: CCKAR, CCKBR
- Drugs: Afatinib, Docetaxel, Rifampin, Candesartan Cilexetil, Chlordiazepoxide, Indocyanine Green Acid Form, Nitazoxanide, Rifaximin, Rimonabant, Abiraterone, acetylcysteine, Aclidinium Bromide, Acyclovir, Allopurinol, Almotriptan, Alogliptin, aminolevulinic acid, Anagrelide, Apixaban, Bosentan, Clofarabine, Clozapine, Crizotinib, Desloratadine, Dihydroergotamine, Erythromycin, Ethambutol, Fulvestrant, Ganciclovir, Gefitinib, Glycopyrrolate, Linagliptin, Methotrexate, Olanzapine, Olmesartan Medoxomil, Pramipexole, Propoxyphene, Pyrazinamide, Rufinamide, saxagliptin, Sildenafil, Tadalafil, Tafamidis, Tamsulosin, Tegaserod, Valacyclovir, Valganciclovir, Atazanavir, Fidaxomicin, Amsacrine, Apomorphine, Azlocillin, Bepridil, Cannabidiol, Chlorhexidine, Clotrimazole, Dasatinib, Daunorubicin, Deserpidine, Desogestrel, Efavirenz, Encorafenib, Erlotinib, Flunitrazepam, Fluoxetine, Flutrimazole, Fluvastatin, Hydroxocobalamin, Iloperidone, Isradipine, Lansoprazole, Leflunomide, Letermovir, Lurasidone, Nefazodone, Nimesulide, Osimertinib, Paclitaxel, Pentagastrin, Pimozide, Ramatroban, Ritonavir, Sunitinib, Tamoxifen, Telmisartan, Telotristat, Telotristat Ethyl, Tipranavir, Nilvadipine